Summary
Becton, Dickinson and Company (BDX) reported revenues of $21.84 billion for the fiscal year ending September 30, 2025, an increase of 8.2% year-over-year. This growth was primarily driven by the acquisition of Edwards Lifesciences' Critical Care product group, now known as BD Advanced Patient Monitoring, which contributed 4.8% to the revenue increase. The company continues to navigate a dynamic market, focusing on its strategic objectives of growth, simplification, and empowerment. BD also announced its definitive agreement to combine its Biosciences and Diagnostic Solutions business with Waters Corporation in a Reverse Morris Trust transaction, expected to close by the end of the first quarter of calendar year 2026, which will result in BD shareholders owning approximately 39.2% of the combined entity. Key operational highlights include continued growth across its Medical and Interventional segments, although the Life Sciences segment experienced a slight revenue decline. The company faces ongoing challenges related to supply chain disruptions, inflation, and regulatory complexities, particularly concerning the FDA's consent decree for its Alaris infusion pump business and a recent warning letter for its dispensing quality management system. BD is actively managing these challenges and investing in innovation and operational efficiency to drive future growth and shareholder value.
Financial Highlights
56 data points| Revenue | $21.84B |
| Cost of Revenue | $11.91B |
| Gross Profit | $9.93B |
| R&D Expenses | $1.26B |
| SG&A Expenses | $5.28B |
| Operating Expenses | $19.26B |
| Operating Income | $2.58B |
| Interest Expense | $613.00M |
| Net Income | $1.68B |
| EPS (Basic) | $5.83 |
| EPS (Diluted) | $5.82 |
| Shares Outstanding (Basic) | 287.65M |
| Shares Outstanding (Diluted) | 288.51M |
Key Highlights
- 1BDX reported FY2025 revenues of $21.84 billion, an 8.2% increase year-over-year, largely boosted by the acquisition of BD Advanced Patient Monitoring.
- 2The company entered into a definitive agreement to combine its Biosciences and Diagnostic Solutions business with Waters Corporation via a Reverse Morris Trust transaction, expected to close by Q1 2026.
- 3The Medical segment saw robust revenue growth of 13.7%, driven by strong performance in Medication Delivery Solutions and the addition of Advanced Patient Monitoring.
- 4The Interventional segment also delivered solid growth of 4.8%, with key contributions from Surgery, Peripheral Intervention, and Urology & Critical Care units.
- 5The Life Sciences segment experienced a slight 0.5% decrease in revenue, primarily due to declines in Diagnostic Solutions and Biosciences, partially offset by growth in Specimen Management.
- 6BD continues to manage significant regulatory matters, including an ongoing consent decree for its Alaris infusion pump business and a recent FDA warning letter related to its dispensing quality management system.
- 7The company repurchased approximately $1 billion of its common stock and paid $1.196 billion in dividends to shareholders in FY2025, demonstrating a commitment to returning value to shareholders.